Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
2022 · Cancer Immunology Immunotherapy · 30 citations
https://doi.org/10.1007/s00262-022-03151-2
M
Mitchell S. von Itzstein
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
589
Citations
13
h-index
20
i10-index
Mitchell S. von Itzstein is an academic researcher from Griffith University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & RNA modifications and cancer. The author has an h-index of 13, co-authored 64 publications.
ORCID: 0000-0003-0530-3169Papers by this author
worksPhase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
2024 · Clinical Cancer Research · 6 citations
https://doi.org/10.1158/1078-0432.ccr-24-1722
Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report
2022 · JTO Clinical and Research Reports · 4 citations
https://doi.org/10.1016/j.jtocrr.2022.100368
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer
2024 · JTO Clinical and Research Reports · 3 citations
https://doi.org/10.1016/j.jtocrr.2024.100751
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer
2025 · The Oncologist · 2 citations
https://doi.org/10.1093/oncolo/oyaf036
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
2023 · Translational Oncology · 1 citations
https://doi.org/10.1016/j.tranon.2023.101689
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat